Prostate Cancer

Prostate Cancer

Circulating Biomarkers Associated With Progression-Free Survival in Metastatic Castration-Resistant Prostate Cancer

November 19 3 min read
An exploratory biomarker analysis of the phase III TALAPRO-2 trial found that circulating tumor DNA burden and reductions in circulating tumor cells were associated with radiographic progression–free survival in patients with metastatic castration-resistant prostate cancer receiving talazoparib plus enzalutamide or enzalutamide alone.

Latest in Prostate Cancer